What Is The 5Q Deletion In Myelodysplastic Syndrome?

The 5q deletion is a specific chromosome abnormality found in the bone marrow cells of some people with myelodysplastic syndrome (MDS). It means a piece of chromosome 5 — the long arm, called 5q — is missing. This matters because doctors use it to diagnose a distinct subtype of MDS, predict how the disease is likely to behave, and choose treatment.

Myelodysplastic syndrome is a group of disorders where the bone marrow does not make healthy blood cells. The 5q deletion is one of the most studied chromosome changes in MDS. It appears in a minority of all MDS cases, but it defines a subtype with features that set it apart from other forms of the disease.

What Is The 5q Deletion In Myelodysplastic Syndrome?

The 5q deletion is a clonal chromosome abnormality. “Clonal” means the change happened in one early blood-forming cell, and that cell passed the same abnormality to all the cells that grew from it.

Chromosomes are the packages of DNA inside every cell. Humans normally have 23 pairs, including two copies of chromosome 5. In the 5q deletion, part of the long arm of one copy of chromosome 5 is lost. The abbreviation for this is del(5q).

The deleted region contains many genes, including several that help control how blood cells grow and mature. When those genes are lost from one copy, the balance shifts. Blood-forming cells in the marrow stop maturing normally. Instead of producing healthy red blood cells, white blood cells, and platelets, the marrow produces defective cells and too few of the ones the body needs.

This is not an inherited condition. The deletion is acquired during a person’s lifetime, in the marrow itself. It is not passed to children.

How Common Is the 5q Deletion?

The 5q deletion is uncommon in absolute terms but well recognized because it defines a clear subtype. It is found in a minority of people with MDS overall. It becomes more frequent with age and is more common in women than in men.

Doctors divide del(5q) MDS into two broad situations:

• Isolated del(5q). The 5q deletion is the only chromosome abnormality found. This is the classic, better-prognosis form.
• Del(5q) with other abnormalities. The 5q deletion appears alongside one or more additional chromosome changes. This generally carries a higher risk and behaves more like higher-risk MDS.

That distinction matters a great deal. Two people can both have “5q deletion MDS” and have very different outlooks depending on whether other chromosome changes are present.

What Causes the 5q Deletion?

No one knows exactly what triggers the 5q deletion in a given person. MDS arises from acquired genetic damage in bone marrow stem cells, and in most cases the specific cause of that damage is not identifiable.

What researchers do understand is the consequence. The deleted segment of chromosome 5 contains genes that normally restrain abnormal blood cell growth and support normal maturation. Losing one copy of those genes does not simply remove them — it disrupts the whole regulatory system in the affected cell line.

Certain broad risk factors are associated with MDS in general, including older age and prior exposure to certain chemotherapy drugs or radiation. But these are general associations for MDS as a whole. They are not specific to the 5q deletion, and most people who develop it have no such exposure.

What Are the Symptoms of 5q Deletion MDS?

The most prominent problem in isolated del(5q) MDS is anemia — a shortage of red blood cells. This is the defining clinical feature for many patients.

Symptoms come from low blood counts, and they tend to build slowly:

• Fatigue and weakness that do not improve with rest
• Shortness of breath with activity
• Pale skin
• Dizziness or lightheadedness

Anemia in del(5q) MDS is often severe and can require regular blood transfusions. Over time, repeated transfusions can lead to iron overload, because the body has no natural way to remove the extra iron. That is a real complication doctors monitor for.

White blood cell and platelet counts may also be low, though less dramatically in the isolated form. Low white cells raise infection risk. Low platelets raise bleeding and bruising risk.

Some people have few or no symptoms at first, and the condition is picked up on a routine blood test.

How Is It Diagnosed?

Diagnosis requires looking at the bone marrow, not just the blood. A blood count can show anemia and other low counts, but it cannot reveal a chromosome deletion.

Two tests are central:

• Bone marrow biopsy and aspiration. A sample of marrow is examined under a microscope. In del(5q) MDS, doctors often see distinctive changes in how the young blood cells look, along with abnormal development of red blood cell precursors.
• Chromosome analysis (cytogenetics). Marrow cells are analyzed to map their chromosomes. This is the test that actually detects the missing piece of chromosome 5 and shows whether other abnormalities are present.

The cytogenetics result is what confirms del(5q) and separates the isolated form from the form with additional changes. That result shapes both prognosis and treatment.

How Is 5q Deletion MDS Treated?

Treatment depends heavily on whether the deletion is isolated, how low the blood counts are, whether the person has symptoms, and their age and overall health.

For people with anemia and symptoms, the main options include:

• Supportive care. Blood transfusions to correct anemia, and antibiotics or other measures when infections occur. This is often the first approach.
• Drugs that stimulate red blood cell production. These are used in some patients to reduce transfusion needs. Response varies, and not everyone benefits.
• Lenalidomide. This is an oral medication that has a specific role in del(5q) MDS. It can reduce or eliminate the need for transfusions in some patients, and in a portion of them it also reduces the abnormal cell population. It is not effective for everyone, and it carries risks, including low blood counts that require monitoring. It is used under the care of a hematologist.
• Disease-modifying therapy. For higher-risk disease or when other treatments stop working, other approaches may be considered, including medicines that affect how abnormal cells grow or, in selected patients, stem cell transplant.

Stem cell transplant is the only treatment with the potential to cure MDS. It is a demanding procedure with serious risks and is generally reserved for patients who are candidates based on age, overall health, and disease risk.

What Is the Outlook for Someone With 5q Deletion MDS?

Outlook depends most on whether the 5q deletion is isolated. Isolated del(5q) MDS generally has a better prognosis than many other MDS subtypes, and some patients live for years with management of their anemia.

When additional chromosome abnormalities are present, the outlook is closer to that of higher-risk MDS. That is why the cytogenetics report is so important.

There is also a small but real risk that MDS can progress to a more aggressive bone marrow cancer, acute myeloid leukemia. This risk is lower in isolated del(5q) MDS and higher when other abnormalities are present. Doctors monitor blood counts over time to watch for signs of progression.

Prognosis is individual. No single number predicts what will happen to one person. A hematologist uses the specific chromosome findings, blood counts, marrow findings, age, and symptoms to give a clearer picture.

Is the 5q Deletion Inherited?

No. The 5q deletion in MDS is acquired, not inherited. It develops in a blood-forming cell during a person’s life and is confined to that cell line. It is not present in a person’s sperm or eggs, so it cannot be passed to children.

This is a common point of confusion. People sometimes worry that a chromosome finding means they have passed something on to their family. In this case, they have not.

What Should Someone With This Diagnosis Know?

The 5q deletion is a specific finding, not a vague label. It tells doctors something concrete about the biology of the disease and helps guide treatment.

The single most useful piece of information for any patient is whether their deletion is isolated or accompanied by other chromosome changes. That one detail changes the prognosis and the treatment conversation.

MDS is managed by hematologists, often at centers with experience in bone marrow disorders. Because treatments and monitoring are individualized, the right next step for one person may not be right for another. Questions about a specific case belong with the treating specialist, who has the full marrow and chromosome results.